• Jazz Pharmaceuticals raised its 2026 revenue forecast to $4.78 billion-$4.85 billion from $4.6 billion-$4.75 billion.
• Third-quarter revenue rose 10% to $1.24 billion, driven by oncology and Xywav growth.
• Rare sleep revenue is now expected at $2.13 billion-$2.18 billion, with Xywav growth projected at low double digits to low teens.
• Adjusted gross margin guidance increased to 90.5%-91.5% from 90%-91%, reflecting higher revenue expectations.
• The adjusted effective tax rate forecast rose to 19.5%-21.5% from 11.5%-13.5%, reflecting non-tax-deductible acquired research charges from the Actio acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.